EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Approach to the Patient With Prolactinoma

Renata S Auriemma, Rosa Pirchio iD, Claudia Pivonello, Francesco Garifalos, Annamaria Colao, Rosario Pivonello iD

The Journal of Clinical Endocrinology & Metabolism · 18.08.2023 · 108 (9) · 2400-2423

DOI: 10.1210/clinem/dgad174 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.03.2023. Verfasst von Renata S Auriemma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Prolactinoma, Pituitary Neoplasms, Hypogonadism. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 243 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prolactinomas are the most common pituitary tumor histotype, with microprolactinomas being prevalent in women and macroprolactinomas in men. Hyperprolactinemia is among the most common causes of hypogonadotropic hypogonadism in both sexes, prompting medical advice for hypogonadism (infertility, oligo-amenorrhea, impotence, osteoporosis/osteopenia) in both sexes, and for signs and symptoms of mass effects (hypopituitarism, visual loss, optic chiasm compression, cranial nerve deficits, headaches) predominantly in men. Diagnostic workup involves a single prolactin measurement and pituitary imaging, but some laboratory artifacts (ie, the “hook effect” and macroprolactin) can complicate or delay the diagnosis. The treatment of choice for prolactinomas is represented by dopamine agonists, mainly cabergoline, which are able to induce disease control, restore fertility in both sexes, and definitively cure one-third of patients, thus permitting treatment discontinuation. Pregnancy and menopause may promote spontaneous prolactin decline and anticipate cabergoline discontinuation in women. Surgery and/or radiotherapy are indicated in case of resistance to cabergoline not overcome by the increase in drug dose up to the maximally tolerated or the patient's personal choice of surgery. The evidence of resistance to cabergoline in invasive and proliferative tumors may indicate biological aggressiveness, thus requiring alternative therapeutic approaches mainly based on temozolomide use as monotherapy or combined with radiotherapy. In uncontrolled patients, new medical approaches (alternative hormonal treatments, cytotoxic drugs, peptide receptor radionuclide therapy, mTOR/Akt inhibitors, tyrosine kinase inhibitors, or immunotherapy) may be offered but the experience collected to date is still very scant. This article reviews different facets of prolactinomas and discusses approaches to the condition in more common clinical situations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProlactinomaPituitary NeoplasmsHypogonadismMalePregnancyHumansFemaleCabergolineProlactinErgolinesDopamine Agonists

Stichwörter der Autor:innen

cabergolinedopamine agonistshyperprolactinemiamenopausepituitary tumorpregnancyprolactintreatment withdrawal

Substanzen

CabergolineProlactinErgolinesDopamine Agonists

Autor:innen und Institutionen

  • Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, 80131 Naples, Italy.
  • Dipartimento di Sanità Pubblica, Università Federico II di Napoli, 80131 Naples, Italy.
  • Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Unità di Andrologia e Medicina della Riproduzione e Sessualità Maschile e Femminile (FERTISEXCARES), Università Federico II di Napoli, 80131 Naple…
  • Unesco Chair for Health Education and Sustainable Development, "Federico II" University, 80131 Naples, Italy.

ORCID-Profile: Rosa Pirchio, Rosario Pivonello

Zitieren

APA

Auriemma, R. S., Pirchio, R., Pivonello, C., Garifalos, F., Colao, A., & Pivonello, R. (2023). Approach to the Patient With Prolactinoma. The Journal of Clinical Endocrinology & Metabolism, 108(9), 2400-2423. https://doi.org/10.1210/clinem/dgad174

Vancouver

Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R. Approach to the Patient With Prolactinoma. The Journal of Clinical Endocrinology & Metabolism. 2023;108(9):2400-2423. doi:10.1210/clinem/dgad174

BibTeX
@article{Auriemma2023,
  author = {Auriemma, Renata S and Pirchio, Rosa and Pivonello, Claudia and Garifalos, Francesco and Colao, Annamaria and Pivonello, Rosario},
  title = {Approach to the Patient With Prolactinoma},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {9},
  pages = {2400--2423},
  doi = {10.1210/clinem/dgad174}
}
Kostenlos starten →